Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-27
DOI
10.1186/s12967-020-02306-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
- (2019) Neeta Somaiah et al. CLINICAL CANCER RESEARCH
- TCR-like antibodies in cancer immunotherapy
- (2019) Qinghua He et al. Journal of Hematology & Oncology
- Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy
- (2018) Olga Gordeeva SEMINARS IN CANCER BIOLOGY
- NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer
- (2017) J. Brian Szender et al. GYNECOLOGIC ONCOLOGY
- Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.
- (2017) Tiphaine Delaunay et al. OncoImmunology
- Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance
- (2016) Christopher J Nirschl et al. Human Vaccines & Immunotherapeutics
- SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
- (2016) Wei Xue et al. OncoImmunology
- Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope
- (2016) P. Baumgaertner et al. OncoImmunology
- LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
- (2016) Tina Chang Albershardt et al. Molecular Therapy-Oncolytics
- A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
- (2015) Deepa K. Krishnadas et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
- (2015) Oliver Klein et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
- (2015) E. K. Moon et al. CLINICAL CANCER RESEARCH
- New York esophageal squamous cell carcinoma-1 and cancer immunotherapy
- (2015) Ali Esfandiary et al. Immunotherapy
- NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers
- (2015) Yoko Oshima et al. JOURNAL OF GASTROENTEROLOGY
- Landscape of Tumor Antigens in T Cell Immunotherapy
- (2015) S. Ilyas et al. JOURNAL OF IMMUNOLOGY
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
- (2015) Richard G. Everson et al. NEURO-ONCOLOGY
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Oncogenic cancer/testis antigens: prime candidates for immunotherapy
- (2015) Morten F. Gjerstorff et al. Oncotarget
- T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma
- (2015) Nathan Singh et al. OncoImmunology
- The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells
- (2015) Madhav Sharma et al. Journal for ImmunoTherapy of Cancer
- Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
- (2015) Agnes S. Klar et al. PLoS One
- Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
- (2014) Tim Luetkens et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
- (2014) Z K Klippel et al. GENE THERAPY
- Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer
- (2014) Simon Laban et al. INTERNATIONAL JOURNAL OF CANCER
- Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens
- (2014) Stephen J Hayes WORLD JOURNAL OF GASTROENTEROLOGY
- Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer
- (2014) YAN-YAN LONG et al. Experimental and Therapeutic Medicine
- Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
- (2013) Dimitrios Balafoutas et al. BMC CANCER
- NY-ESO-1 antibody as a novel tumour marker of gastric cancer
- (2013) S Fujiwara et al. BRITISH JOURNAL OF CANCER
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma
- (2013) Phyu P. Aung et al. HUMAN PATHOLOGY
- Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
- (2013) Nancy E. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
- (2013) Tvrtko Hudolin et al. Journal of Translational Medicine
- NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms
- (2013) Jessica A Hemminger et al. MODERN PATHOLOGY
- Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients’ sera using short overlapping peptides and full-length recombinant protein
- (2013) Nobukazu Komatsu et al. MOLECULAR IMMUNOLOGY
- Design of a Novel Integration-deficient Lentivector Technology That Incorporates Genetic and Posttranslational Elements to Target Human Dendritic Cells
- (2013) Semih U Tareen et al. MOLECULAR THERAPY
- NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches
- (2013) G. S. Baia et al. Cancer Immunology Research
- NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
- (2012) Seth M. Pollack et al. CANCER
- Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
- (2012) P C Schuberth et al. GENE THERAPY
- NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis
- (2012) Jin-Ping Lai et al. MODERN PATHOLOGY
- The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas
- (2012) Jessica A Hemminger et al. MODERN PATHOLOGY
- HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression
- (2012) Pierre-François Cartron et al. Molecular Oncology
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
- (2011) Theo Nicholaou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers
- (2011) Yao-Tseng Chen et al. PLoS One
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination
- (2011) Iana Parvanova et al. VACCINE
- Translating Tumor Antigens into Cancer Vaccines
- (2010) Luigi Buonaguro et al. Clinical and Vaccine Immunology
- Strategies for Cancer Vaccine Development
- (2010) Matteo Vergati et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact
- (2010) James E. Talmadge SEMINARS IN CANCER BIOLOGY
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
- (2009) J. Fourcade et al. JOURNAL OF IMMUNOLOGY
- CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
- (2008) L. G. Almeida et al. NUCLEIC ACIDS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started